Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Ligand Pharmaceuticals Incorporated (NASDAQ: LGND).

Full DD Report for LGND

You must become a subscriber to view this report.

Recent News from (NASDAQ: LGND)

Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31
"R&D Renaissance" in Drug Development
The healthcare sector is among the most innovative in the country, and the industry is in fact in an “R&D Renaissance” period, as drug makers are rolling out promising new products to treat cancer, multiple sclerosis, diabetes and other diseases, explains John Eade , analys...
Date: August, 30 2018 01:00
Ligand to Participate in H.C. Wainwright 20th Annual Global Investment Conference
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in H.C. Wainwright 20 th Annual Global Investment Conference in New York City. Presentation takes place on Wednesday, September 5, 2018 at 12:30 p.m. Eastern time (9:30 a.m. Pacific t...
Source: Business Wire
Date: August, 29 2018 09:00
By The Numbers: Growth Leaders With Strong Momentum
Investing in high-growth stocks can generate outstanding returns when done right. In essence, a stock is simply a share in the ownership of a business, and businesses with superior growth rates tend to generate higher returns for investors over the long term. However, implementing a solid gr...
Source: SeekingAlpha
Date: August, 28 2018 10:24
Today's Research Reports on Trending Tickers: Ligand Pharmaceuticals and Geron
NEW YORK, NY / ACCESSWIRE / August 20, 2018 / U.S. equities continued to rally in Friday as hopes of easing trade tensions between the U.S. and China outweighed recent concerns of the currency crisis in Turkey. The Dow Jones Industrial Average jumped 0.43 percent to close at 25,669.32, up b...
Date: August, 20 2018 08:00
Ligand: My Favorite Biotech Stock
Ligand Pharmaceuticals ( LGND ) Ligand Pharmaceuticals, is a San Diego, California-based biotechnology company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs. The stock has been hitting new all-time highs recently. It has a...
Source: SeekingAlpha
Date: August, 20 2018 07:59
Ligand Makes Offer to Acquire Vernalis, a Leader in Structure-Based Drug Discovery, For Approximately $43 Million in Cash
Ligand to gain broad portfolio of partnered and unpartnered programs, a self-funding R&D group and approximately $32 million of net cash Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Vernalis plc (LSE: VER) announce that Ligand has declared its firm intention to acq...
Source: Business Wire
Date: August, 09 2018 08:08
Today's Research Reports on Trending Tickers: Editas Medicine and Ligand Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / U.S. markets closed in the green on Monday, as Nasdaq surged for the fifth consecutive session, on a batch of strong corporate earnings, amidst ongoing trade-related concerns between U.S. and China. The Dow Jones Industrial Average increased 0.16 ...
Date: August, 07 2018 08:00
Ligand's (LGND) CEO John Higgins on Q2 2018 Results - Earnings Call Transcript
Ligand Pharmaceuticals Incorporated (LGND) Q2 2018 Results Earnings Conference Call August 6, 2018, 4:30 PM ET Executives Todd Pettingill - Director, Corporate Development and IR John Higgins - Chief Executive Officer Matt Foehr - President and COO Matt Korenberg - Chief Financ...
Source: SeekingAlpha
Date: August, 06 2018 22:43
Ligand Pharma Q2 top line up 221%; non-GAAP earnings up 307%; guidance raised
Ligand Pharmaceuticals (NASDAQ: LGND ) Q2 results ($M): Revenues: 90.0 (+221.4%); royalties: 31.4 (+43.4%). More news on: Ligand Pharmaceuticals Incorporated, Healthcare stocks news, Earnings news and commentary, Read more ...
Source: SeekingAlpha
Date: August, 06 2018 16:28


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on LGND.

About Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

Logo for Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)

Ligand discovers, develops and markets new drugs for critical unmet medical needs in the areas of cancer, pain, skin diseases, hormone related diseases, osteoporosis, metabolic disorders, cardiovascular and inflammatory diseases. Ligand s proprietary drug discovery and development programs are based on its leadership position in gene transcription technology related to intracellular receptors.


Contact Information



Current Management

  • David A. Robinson / President, CEO
  • Matthew A. Foehr / President, COO
  • John Higgins / President, CEO
    • Mr. Higgins served as Chief Financial Officer and Executive Vice President, Finance and Administration and Corporate Development, of Connetics Corporation, a specialty pharmaceutical company acquired by Stiefel Laboratories in . Before joining Connetics, he was a member of the executive management team at BioCryst Pharmaceuticals. Currently, he is a Director on the Boards of Techne Corporation, CoMentis and BioCryst and serves as Chairperson of the Techne Audit Committee. Prior to BioCryst, Mr. Higgins was a member of the healthcare banking team of Dillon, Read amp Co. Inc., an investment banking firm. He graduated Magna Cum Laude from Colgate University with an AB in economics.
  • Nishan de Silva / CFO
  • Matthew Korenberg / CFO, VP, Fin., Principal Acct. Officer
    • Mr. Korenberg has more than eighteen years of healthcare business experience across healthcare investing banking and operations. Prior to joining Ligand, commencing in September , Mr. Korenberg was the founder, Chief Executive Officer and a director of NeuroCircuit Therapeutics, a company focused on developing drugs to treat genetic disorders of the brain with an initial focus on Down syndrome. Prior to founding NeuroCircuit Therapeutics, Mr. Korenberg was a Managing Director and member of the healthcare investment banking team at Goldman Sachs from July through August . During his fourteen year tenure at Goldman Sachs, Mr. Korenberg was focused on advising and financing companies in the biotechnology and pharmaceutical sectors and was based in New York, London and San Francisco. Prior to Goldman Sachs, Mr. Korenberg was a healthcare investment banker at Dillon, Read amp Co. Inc. where he spent two years working with healthcare companies in the biotechnology and pharmaceutical sectors and industrial companies. Mr. Korenberg holds a B.B.A. in Finance and Accounting from The University of Michigan.
  • Charles A. Berkman / Vice President, Secretary, General Counsel
  • Erika Luib / IR
  • David A. Robinson / Chairman
  • Dr. Nancy Ryan Gray / Director
    • Dr. Gray, , has acted as the President and CEO of Gordon Research Conferences, a nonprofit organization focused on organizing international scientific conferences, since . From December until August she served as the Director of Membership for the American Chemical Society. Prior to that, Dr. Gray worked as a Senior Research Scientist at Exxon/Mobil Research and Engineering, a subsidiary of Exxon Mobil Corporation focused on researching oil and gas. Dr. Gray received her B.S. in Chemistry from the University of Notre Dame in and her Ph.D. in Fuel Science from The Pennsylvania State University in .
  • John LaMattina /
  • Sunil Patel /

Current Share Structure


    Recent Filings from (NASDAQ: LGND)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 10 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: May, 09 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: May, 08 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: April, 30 2018
    Additional proxy soliciting materials - definitive
    Filing Type: DEFA14AFiling Source: edgar
    Filing Date: April, 30 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: April, 13 2018
    Filing Type: CT ORDERFiling Source: edgar
    Filing Date: April, 03 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 22 2018
    Amendment to a previously filed 8-K
    Filing Type: 8-K/AFiling Source: edgar
    Filing Date: March, 07 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: March, 06 2018



    Daily Technical Chart for (NASDAQ: LGND)

    Daily Technical Chart for (NASDAQ: LGND)

    Stay tuned for daily updates and more on (NASDAQ: LGND)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: LGND)

    Do your DD and if you choose, be ready to go!


    The Research: All source information contained in this email is from the public sources mentioned below.



    Thank you

    DD Report



    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in LGND is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of LGND and does not buy, sell, or trade any shares of LGND. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: